Pulmonary Vasculature

Latest News

Increased Risk for Adverse Outcomes With Mild Pulmonary Hypertension in HFpEF

Viewing mild pulmonary hypertension as a high-risk clinical parameter in heart failure with preserved ejection fraction could pave a way forward for early intervention.

Effects of Staged Balloon Pulmonary Angioplasty for CTEPH on Renal Function

Balloon pulmonary angioplasty therapy improves pulmonary and systemic hemodynamics, with positive effects on renal function.

Combined Automated 3D Volumetry and Echocardiography Detects PH

Investigators used computed tomography pulmonary angiography to evaluate the diagnostic accuracy of automated 3D volumetry of central pulmonary arteries for suspected pulmonary hypertension alone and in combination with echocardiography.

Six Radiologic Parameters May Predict CTEPH in Acute Pulmonary Embolism

Expert radiologists can accurately identify patients who will later be diagnosed with CTEPH by evaluating the computed tomography pulmonary angiogram scan performed in the setting of suspected acute pulmonary embolism using 6 standardized radiologic parameters.

Incremental Shuttle Walk Test Predicts Outcomes in Non-Group 1 PH

The Incremental Shuttle Walk Test is predictive of survival in patients with both Group 1 pulmonary arterial hypertension and Groups 2, 3, and 4 pulmonary hypertension.

Patent Foramen Ovale Increases Ischemic Stroke in Those With PE

For patients with symptomatic pulmonary embolism, the frequency of recent ischemic stroke is higher in those with PFO.

CTEPH May Improve With Extracorporeal Membrane Oxygenation After PEA

Extracorporeal membrane oxygenation may be beneficial for patients with thromboembolic pulmonary hypertension after pulmonary endarterectomy for cardiac and respiratory complications.

Subcutaneous Delivery System for Remodulin Cleared by FDA

The FDA has cleared the Unity Subcutaneous Delivery System for Remodulin (treprostinil) Injection, also known as the RemUnity system.

Beraprost May Improve Cardiopulmonary and Exercise Capacity in PH-HFrEF

The addition of beraprost to the usual treatment of pulmonary hypertension due to left ventricular systolic dysfunction may improve cardiopulmonary hemodynamic and exercise capacity.

Early Triple Combination Therapy With Selexipag Stabilizes Functional Class in PAH/CTEPH

Researchers sought to determine whether add-on therapy with the novel oral selective prostacyclin receptor agonist selexipag is beneficial for patients with pulmonary arterial hypertension and distal chronic thromboembolic pulmonary hypertension with intermediate risk.